Autism spectrum disorders and disease modeling using stem cells
- PMID: 28918504
- DOI: 10.1007/s00441-017-2685-x
Autism spectrum disorders and disease modeling using stem cells
Abstract
Autism spectrum disorders (ASD) represent a variety of disorders characterized as complex lifelong neurodevelopment disabilities, which may affect the ability of communication and socialization, including typical comportments like repetitive and stereotyped behavior. Other comorbidities are usually present, such as echolalia, hypotonia, intellectual disability and difficulties in processing figured speech. Furthermore, some ASD individuals may present certain abilities, such as eidetic memory, outstanding musical or painting talents and special mathematical skills, among others. Considering the variability of the clinical symptoms, one autistic individual can be severely affected in communication while others can speak perfectly, sometimes having a vocabulary above average in early childhood. The same variability can be seen in other clinical symptoms, thus the "spectrum" can vary from severe to mild. Induced pluripotent stem cell technology has been used to model several neurological diseases, including syndromic and non-syndromic autism. We discuss how modeling the central nervous system cells in a dish may help to reach a better understanding of ASD pathology and variability, as well as personalize their treatment.
Keywords: ASD; Autism spectrum disorders; Disease modeling; Stem cells; iPSC.
Similar articles
-
Modeling the Interplay Between Neurons and Astrocytes in Autism Using Human Induced Pluripotent Stem Cells.Biol Psychiatry. 2018 Apr 1;83(7):569-578. doi: 10.1016/j.biopsych.2017.09.021. Epub 2017 Oct 3. Biol Psychiatry. 2018. PMID: 29129319
-
Human Inducible Pluripotent Stem Cells and Autism Spectrum Disorder: Emerging Technologies.Autism Res. 2016 May;9(5):513-35. doi: 10.1002/aur.1570. Epub 2015 Oct 1. Autism Res. 2016. PMID: 26426199 Review.
-
Modeling autism spectrum disorders with human neurons.Brain Res. 2017 Feb 1;1656:49-54. doi: 10.1016/j.brainres.2016.01.057. Epub 2016 Feb 5. Brain Res. 2017. PMID: 26854137 Free PMC article. Review.
-
The use of iPSC technology for modeling Autism Spectrum Disorders.Neurobiol Dis. 2019 Oct;130:104483. doi: 10.1016/j.nbd.2019.104483. Epub 2019 May 24. Neurobiol Dis. 2019. PMID: 31129084 Review.
-
Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD.Dev Growth Differ. 2016 Jun;58(5):481-91. doi: 10.1111/dgd.12280. Epub 2016 Apr 25. Dev Growth Differ. 2016. PMID: 27111774 Review.
Cited by
-
Cultures and cures: neurodiversity and brain organoids.BMC Med Ethics. 2021 May 17;22(1):61. doi: 10.1186/s12910-021-00627-1. BMC Med Ethics. 2021. PMID: 34001098 Free PMC article.
-
PLPPR4 haploinsufficiency causes neurodevelopmental disorders by disrupting synaptic plasticity via mTOR signalling.J Cell Mol Med. 2023 Nov;27(21):3286-3295. doi: 10.1111/jcmm.17899. Epub 2023 Aug 7. J Cell Mol Med. 2023. PMID: 37550884 Free PMC article.
-
Neural stem cells: developmental mechanisms and disease modeling.Cell Tissue Res. 2018 Jan;371(1):1-6. doi: 10.1007/s00441-017-2738-1. Cell Tissue Res. 2018. PMID: 29196810 Free PMC article.
-
Mental health dished up-the use of iPSC models in neuropsychiatric research.J Neural Transm (Vienna). 2020 Nov;127(11):1547-1568. doi: 10.1007/s00702-020-02197-9. Epub 2020 May 7. J Neural Transm (Vienna). 2020. PMID: 32377792 Free PMC article.
-
Patient-Derived Induced Pluripotent Stem Cells (iPSCs) and Cerebral Organoids for Drug Screening and Development in Autism Spectrum Disorder: Opportunities and Challenges.Pharmaceutics. 2021 Feb 19;13(2):280. doi: 10.3390/pharmaceutics13020280. Pharmaceutics. 2021. PMID: 33669772 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical